New Book/2016, Hematological and Metabolical Aspects of Laboratory Medicine, www.amazon.com

chronic lymphocytic leukemia, p-53 protein, apoptosis, ZAP-70, CD38 receptor.

Author agreement Short presentation of the project, mentioning the proposed targets to be achieved by implementing the project In recent years, the technique of gene analysis, chromosome rearrangement, cross reactivity, or multiplication in the human genome affected by a variety of genetic diseases has been used. It has been demonstrated that the best techniques for investigating malignant lymphocytes are flow cytometry and in situ hybridization fluorescence (FISH). The latter method, FISH, is used as an alternative to chromosomal bandage, a conventional application in molecular medicine and can detect gene deletions, chromosomal and complex rearrangements of various genes in malignant diseases such as chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia) or multiple myeloma (MM). In particular, the identification of P53 gene deletions and mutations in chromosome 17 regions in hematological malignancies is important because these genetic events have an impact on the clinical management of patients. Completing personal research using the FISH molecular technique could contribute to a new breakthrough in treating cancer, especially in CLL, the most common form of adult leukemia. Identifying different mutations is important because these mutations have an impact on patients' clinical course and require an appropriate adjustment of the therapeutic attitude. High concentrations of anaerobic ATP may affect CLL apoptosis. Further studies are needed to detect in patients with high concentrations of ATP mutations or translocations deletions of the p53 gene using complex molecular technologies to discover the complete mechanism in the carcinogenesis process (Udriştioiu A, Florescu C, Popescu AM, Cojocaru M. High concentration of anaerobic ATP involved in aborted apoptosis from CLL, Lab. Med 41: 2010: 203-8). Current state of the research topic In the country, Romania The application of ELISA and FISH technology in highly specialized laboratories from research institutions funded by European programs in cases of malignant patients resistant to conventional classical therapy, chemotherapy has not been published in scientific papers in the country. The subsequent recently published the significance of p-53 proteins in triggering malignant hematopoiesis, (Udristioiu Aurelian, Nica-Badea Delia. Biomedicine & Pharmacotherapy. Significance of protein p-53 isoforms and immune therapeutic success in chronic lymphocytic leukemia. Volume 106, October 2018, pages 50-53; Indexing in the PubMed Web of Science (WOS). In abroad: In international studies. expression of unchanged immunoglobulin heavy chain variable (IGHV) genes, ZAP-70 proteins, CD38 receptor, and chromosomal anomalies such as 17p deletions have been associated with poor prognosis for non-Hodgkin's lymphomas. In addition, mutations in tumor suppressor genes, such as P-53 and ATM, have been associated with resistance to conventional chemotherapeutic agents. Modifications of micro-RNA expression and aberrant methylation patterns in genes that are specifically deregulated in CLL, including the BCL-2, TCL1 and ZAP-70 genes, have also been encountered and related to distinguished clinical parameters. Specific chromosomal abnormalities and genetic mutations can serve as diagnostic and prognostic indicators for disease progression and survival. The effectiveness of new therapists should be tested for the presence of these molecular lesions in CLL patients. P53 mutations are the most common genetic abnormalities of cancer. They have been extensively studied in various mature B cell malignancies, including CLL. In recent years, more attention has been paid to the importance of the p53expressed protein in CLL, and a combination with low survival and non-response to classical conventional chemotherapy and radiotherapy therapy has been observed in a number of cases of CLL with the p-53 protein mutant or absence as a consequence of P-53 gene deletion. -Aurelian Udristioiu, M.D, Primary Physician Laboratory Medicine, City Targu Jiu, -Romania. -National Academy of Biochemical Chemistry NACB/AACC Member, Washington D.C, USA -PhD in Molecular Biology, Titu Maiorescu University, General Medicine Faculty, Bucharest, Romania. -Man of medical year/2015, Award, International Bibliographic Center, Cambridge, UK. -Aurelian Udristioiu, Certificate as Award Academic, IBC, International Bibliographic Centre, Cambridge, UK, 2017. -” Marquis Who's Who” Lifetime /2018, 300 Connell Drive, Suite 2000, Berkeley Heights, N0: 07922 USA1-908-673-1000 , www.marquiswhoswho.com -Membership of Cancer Epigenetics Society. Membership ID number is: 786. Web: https://ces.b2sg.org/, Union for International Cancer C